Skip to main content
. Author manuscript; available in PMC: 2011 May 10.
Published in final edited form as: Liver Transpl. 2000 Nov;6(6):686–702. doi: 10.1053/jlts.2000.19029

Figure 3.

Figure 3

The myeloid (i.e., CD11b/c+) fraction (light shading) of LEW-specific MHC class II+ (L21-6+) leukocytes in cell suspensions prepared from normal LEW hearts (group 0) and LEW isografts (group 1) and allografts (groups 2 through 6) 5 and 100 days after transplantation. Note that 59% to 85% of the L21-6+ cells are myeloid derived except in the 100-day hearts of recipients under active TAC therapy, in which the L21-6+ CD11b/c+ cells are a distinct minority (33%).